Flu Treatment Using Lipid Target
Lipid mediator Leukotriene B4 is capable of reducing tissue damage from the flu
Faculty
View recent posts and news from our respiratory research faculty members. For our faculty profiles, read more here: https://meakinsmcgill.com/faculty-members/
Anti-TB Drugs can Increase Risk of TB Re-Infection
Vulnerability of the host to Mycobacterium tuberculosis infection is due to a compromised gut microbiota
A New Enzyme Target for Antibiotics
Dr. Dao Nguyen identifies promising cellular target that could make current and new antibiotics more effective
Beyond Killing Tuberculosis
Publication by Maziar Divangahi and Nargis Khan in Science Immunology
Flu Vaccine and Immunotherapies
Meet RIPK3: a biological weapon to combat the flu
Airway Branching Associated with COPD Risk
Our natural variation in lung anatomy is associated with greater risk of COPD.
BCG-iv Induces Innate Immune Protection Against M. tuberculosis
Cell publication on how BCG induces innate immune protection against M. Tuberculosis
Dr. Basil Petrof Appointed Director of the Meakins-Christie Laboratories
Dr. Basil Petrof appointed Director of the Meakins-Christie Laboratories
Prognostic and Therapeutic Utility of Human Antigen R (HUR) in Idiopathic Pulmonary Fibrosis
New funding to Dr. Carolyn Baglole to study human antigen R (HUR) in pulmonary fibrosis.
STAT6-IP Reduces the Development of Allergic-type Lung Inflammation and Airway Hyperresponsiveness
Scientists discover peptide that could reduce the incidence of RSV-related asthma.